Login | Register

New hepatitis C drug shows promising results in phase II trials

Promising results from a phase II trial published in the journal Gastroenterology suggest adding the new drug danoprevir to the current standard care (peginterferon and ribavirin) for patients with hepatitis C leads to high rates of remission. The results raise hopes that Roche's new drug can improve the quality of life for patients with hepatitis C. Lead author Dr...

Read More

Leave a Reply

Your email address will not be published. Required fields are marked *